NIH NCATS: What It Funds and How to Apply

NIH NCATS is the National Center for Advancing Translational Sciences, the NIH institute whose stated mission is to “turn research observations into health solutions through translational science.” For research administrators the practical point is that NCATS funds through a few distinct routes: institutional hub awards under the Clinical and Translational Science Awards (CTSA) Program, a set of training and career mechanisms attached to that program, and separate rare disease programs. Each route has its own funding opportunity announcement, and eligibility is set in that announcement, not in a general NCATS rule. This guide maps the mechanisms to their purposes, as described on the official NCATS pages, checked 2026-10-29.

What NCATS is and who runs it

NCATS is one of the NIH institutes and centers. Its overview page says “We were established in 2011 to transform the translational process” and gives its vision as “more treatments for all people more quickly.” The NCATS funding menu lists open funding opportunities, small business programs, scientific review, challenges and prize competitions, and conference grant information.

Translational science here means the work of moving a discovery toward patient benefit. For the stage vocabulary that proposals use, see how to describe T0-T4 translational research stages and the dictionary entry for translational research.

Eligibility: set in each funding opportunity

The NCATS CTSA Program page does not state eligibility requirements, and the applicant information page directs applicants to the funding opportunity for each mechanism. Treat the notice of funding opportunity as the controlling document for who may apply; our guide to the notice of funding opportunity explains how to read one. Do not infer eligibility for a training grant from the hub award, or the reverse: they are separate announcements.

One structural fact helps when searching NIH RePORT: the institutions funded through the CTSA Program appear there as “Hub Awards.” The CTSA page says more than 60 leading medical institutions across the nation receive CTSA Program funding.

What NCATS funds

The CTSA Program

The CTSA Program “supports a national network of medical institutions that speeds the translation of research discoveries.” Its stated goals include partnerships that advance translational projects at local, regional and national levels, a national resource for rapid response to urgent public health needs, and training and career support for translational scientists.

The applicant information page lists these mechanisms and announcement numbers:

Mechanism	Announcement listed
UM1 Clinical and Translational Science Award (Clinical Trial Optional)	PAR-24-272
K12	PAR-25-196
R25	PAR-25-197
T32 predoctoral	PAR-25-194
T32 postdoctoral	PAR-25-195
R03 Small Grant	PAR-25-155
RC2 Specialized Innovation Award	PAR-25-156
Collaborative Innovation Awards	PAR-25-296
Conference Grants	NCATS-specific guidance

Announcement numbers are reissued over time, so confirm the current number on the NCATS page before building a submission plan. For the training mechanisms in general, see the dictionary entry for the T32 training grant.

Rare disease programs

NCATS’s research activities page describes these rare disease efforts:

Bespoke Gene Therapy Consortium (BGTC): “developing platforms and standards to speed the development and delivery of gene therapies for rare diseases.”
Clinical Trial Readiness for Rare Diseases, Disorders and Syndromes (CTR) Grants Program: grants for projects focused on collecting data needed to advance promising therapies and diagnostics for rare diseases.
Diagnostic Odyssey: listed in the NCATS navigation as a rare disease effort.
Gene-Targeted Therapies: “developing generalizable approaches to advance gene-targeted therapies for many rare diseases.”

The same page and its navigation also name the Rare Diseases Clinical Research Network (RDCRN), the Rare Diseases Registry Program (RaDaR) and Therapeutics for Rare and Neglected Diseases (TRND).

Other funding areas

The NCATS funding menu lists small business programs, challenges and prize competitions, and conference grant information. For small business context, see the dictionary entry for SBIR.

Application steps

The NCATS applicant information page lists application resources per mechanism; it does not set out one sequence for all of them. The resources named for the UM1 hub award (PAR-24-272) are:

The funding opportunity for the mechanism.
The “Application Information and FAQs” page.
The overview diagram (PDF) of application elements.
The CTSA Program UM1 Budget Request Tables, for the budget.
The CTSA Program Summary Data Guide and Templates, for attachments.

These budget tables and the Summary Data Guide apply to the UM1 only. For the R03, the page points to the funding opportunity announcement only. Post-award changes go through the prior approval process described on the NCATS guidance page.

The applicant page lists a CTSA Program contact mailbox ([email protected]). For how prior approval works across NIH awards, see NIH prior approval.

Typical timeline phases

The NCATS pages give no calendar dates, so plan by phase rather than by date, and take every deadline from the announcement itself:

Announcement review: select the mechanism and read its funding opportunity and FAQ page.
Preparation: complete the budget request tables and the summary data attachments.
Submission and review: NCATS lists scientific review in its funding menu; the general NIH sequence is covered in the NIH grant cycle.
Award and post-award: changes after award go through prior approval requests.

Common mistakes

Assuming eligibility from the program page. The CTSA page states none; it lives in each announcement.
Treating the hub award as the only route. The applicant page lists training (K12, R25, T32), small grant (R03), RC2 and collaborative innovation mechanisms as separate announcements.
Skipping the UM1 templates. For the UM1, the page directs applicants to the UM1 Budget Request Tables and the Summary Data Guide and Templates; the budget and attachments are built from them. Other mechanisms, such as the R03, point to their own announcement.
Making post-award changes without approval. The page routes changes through prior approval requests.

Related programs

Program	What the NCATS page says
CTSA Program	National network of medical institutions that speeds translation of research discoveries; funded institutions appear as Hub Awards in NIH RePORT
Bespoke Gene Therapy Consortium	Developing platforms and standards to speed development and delivery of gene therapies for rare diseases
Clinical Trial Readiness (CTR) grants	Grants for projects collecting data needed to advance promising therapies
Diagnostic odyssey effort	Listed in NCATS navigation as a rare disease effort
Gene-Targeted Therapies	Developing generalizable approaches to advance gene-targeted therapies
RDCRN, RaDaR, TRND	Named in NCATS navigation

For comparing institute-level funding outcomes, see NIH paylines by institute for FY2026.

FAQ

What does NCATS stand for?

National Center for Advancing Translational Sciences, an NIH institute. Its mission is to turn research observations into health solutions through translational science.

Does NCATS run the CTSA Program?

Yes. The CTSA Program is listed among NCATS research activities, and funded institutions appear as Hub Awards in NIH RePORT.

Who is eligible to apply?

The CTSA page states no eligibility requirements. Each mechanism’s funding opportunity sets them, so read the announcement for the mechanism you plan to use.

Does NCATS fund rare disease research?

Its research activities page describes the Bespoke Gene Therapy Consortium, the CTR grants program and gene-targeted therapies, lists Diagnostic Odyssey, and names RDCRN, RaDaR and TRND.